cancer1.gif (921 bytes)  cancer2.gif (4815 bytes)

cancer3.gif (4526 bytes)

PRELIMINARY PROGRAM
Educational Objectives:

Upon completion of this workshop, participants should be able to:
  • Describe current MRI/MRS methodologies used to diagnose cancer and to evaluate response to therapies;
  • Explain biostatistics for analyzing MR indices used in diagnosis and therapeutic response monitoring;
  • Evaluate different MRI contrast mechanisms and appropriately select these for specific applications to cancer;
  • Describe some of the unique metabolic/physiologic characteristics of cancer that can be assessed by MRI/MRS;
  • Explain the regulatory issues related to the introduction of new MRI agents;
  • Appraise the current role and expected future directions of MR in the cancer research lab and the cancer clinic.
Friday, 18 October

17:00-19:00

 Registration and Poster set-up

17:30-21:00

 Dinner
Saturday, 19 October

07:00-08:30

 Breakfast/Registration

08:30-08:40

 Welcome
Michael Garwood, Ph.D., University of Minnesota, Minneapolis, MN, USA

08:40-09:30

 Importance of the Tumor Micro-Environment for Response to Therapy
J. Martin Brown, D.Phil., Stanford University, Stanford, CA, USA

09:30-10:40

 Contrast Enhanced MRI
Chair: Boudewijn van der Sanden, Ph.D., INSERM, CHU de Grenoble, Grenoble, France
  • 09:30 - 09:50: Introduction and Overview
    Boudewijn van der Sanden, Ph.D., INSERM, CHU de Grenoble, Grenoble, France
  • 09:50 - 10:10: "New Agents in the Pipeline"
    Michael F. Tweedle, Ph.D., Bracco Research USA, Princeton, NJ, USA
  • 10:10 - 10:40: Proffered Papers:

    "Reproducibility of Dynamic Contrast enhanced MRI in Liver Metastasis of Colorectal Cancer"
    H. van Laarhoven, M.D., M.A., UMC Nijmegen, Nijmegen, Netherlands

    "Simultaneous Measurement of Arterial Input Function and Tumor Perfusion in Mice"
    Rong Zhou, Ph.D., University of Pennsylvania, Philadelphia, PA, USA

    "Contrast-Enhanced MR Guided Genomic and Proteomic Analysis of Squamous Cell Carcinoma Tumor Model Based on Spatial and Temporal Changes"
    Yi-Shan Yang, Stanford University School of Medicine, Stanford, CA, USA

10:40-11:00

 Break

11:00-12:00

 Evaluating Anti-Angiogenic and Other Therapies by MRI
Chair: Ross J. Maxwell, Ph.D., Mount Vernon Hospital, Northwood, England, UK
  • 11:00 - 11:20: Introduction and Overview
    Ross J. Maxwell, Ph.D., Mount Vernon Hospital, Northwood, England, UK
  • 11:20 - 11:40: "Encouraging clinical experience in monitoring anti-angiogenic therapies by MRI"
    Bruno Morgan, M.A., M.R.C.P., F.R.C.R., University of Leicester, Leicester, England, UK
  • 11:40 - 12:00: Proffered Papers:

    "Use of Paramagnetic Contrast Agents for In Vivo Imaging of Tumor Oxygen Status"
    Murali K. Cherukuri, Ph.D., National Cancer Institute, Bethesda, MD, USA

    "BOLD-MRI Responses to Vasoactive Agents:  Influence of Vessel Maturity"
    K.J. Lankester, Gray Cancer Institute, Mount Vernon Hospital, Northwood, England, UK

12:00-13:30

 Lunch

13:30-14:15

“The Need for Better Imaging from an Oncologist’s Perspective”
Douglas Yee, M.D., University of Minnesota Cancer Center, Minneapolis, MN, USA
14:15-14:55 Poster Discussions:
  • "BOLD MRI Response to Hypercapnic Hyperoxia in Patients with Meningiomas: Correlation with Gadolinium-DTPA Uptake Rate"
    M. Rijpkema, M.Sc., UMC Nijmegen, Nijmegen, Netherlands
  • "Blood Volume and Vessel Size Imaging: Histological Validation and Vasculature Characterization in Rat Brain During C6 Glioma Growth"
    Laurent Lamalle, INSERM IFR 1, Grenoble, France
  • "CPMG Measurements of USPIO-Induced  DR2 in C26A Murine Colon Carcinoma"
    Giulio Gambarota, UMC Nijmegen, Nijmegen, Netherlands
  • "MR Imaging and Spectroscopy of Prostate Cancer with an Endorectal Coil at 1.5 and 3 Tesla"
    T.W.J. Scheenen, M.Sc., UMC Nijmegen, Nijmegen, Netherlands
  • "Diffusion Tensor Imaging of the Prostate Following Therapy"
    Albert P. Chen, University of California, San Francisco, CA, USA
14:55-16:10 Poster session 1:  Functional and Molecular Assessment of Cancer
16:10-16:30 Break
16:30-17:50 Other MRI Contrasts in Cancer
Chair:  Risto Kauppinen, M.D., Ph.D., University of Kuopio, Kuopio, Finland
  • 16:30-16:50: “T2* MRI”
    Michal Neeman, Ph.D., Weizmann Institute of Science, Rehovot, USA
  • 16:50-17:10: “T2 and T1p MRI”
    Olli H.J., Gröhn, Ph.D., Center for MR Research, Minneapolis, MN, USA
  • 17:10-17:30: “Diffusion MRI”
    Thomas L. Chenevert, Ph.D., University of Michigan, Ann Arbor, MI, USA
  • 17:30-17:50: “Cell tracking by MRI”
    Jeff W.M. Bulte, Ph.D., Johns Hopkins University, Baltimore, MD, USA

18:00-20:00

 Dinner
Sunday, 20 October
07:00-09:00 Breakfast
09:00-10:30 Special Negendank Session:  Introduction and Overview of Choline Metabolism:  Membrane Turnover and/or Signal Transduction
Chair: Zaver M. Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, MD, USA
  • 9:00-9:15: Introduction and Overview
    Zaver M. Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, MD, USA
  • 9:15-9:40: "Biochemistry of Choline Compounds"
    Dennis E. Vance, Ph.D., F.R.S.C., University of Alberta, Edmonton, AL, Canada
  • 9:40-10:10: "Cancer MR Studies of Choline Compounds - Basic Research Perspective"
    Sabrina M. Ronen, Ph.D., The Royal Marsden Hospital, Surrey, England, UK
  • 10:10-10:30: Proffered Papers:

    "Phosphocholine Response to Low Doses of Taxotere is Quantified and Correlated with other Cellular Responses in Non-tumorigenic, Tumorigenic and Metastatic Breast Cancer Cells"
    David L. Morse, B.S., Arizona Cancer Center, Tucson, AZ, USA

    "Indomethacin-Induced Alterations in Phospholipid Metabolism of Malignant and Non-malignant Human Mammary Epithelial Cells Studied by 1H and 13C NMR"
    Kristine Glunde, Johns Hopkins University School of Medicine, Baltimore, MD, USA
10:30-10:50 Break
10:50-12:15 pH and Lactate
Chair: Marion Stubbs, D.Phil., St. George's Hospital Medical School, London, England, UK
  • 10:50-11:10: "Understanding the Tumor Metabolic Phenotype in the Genomic Era"
    Marion Stubbs, D.Phil., St. George's Hospital Medical School, London, England, UK
  • 11:10-11:30: "Comparison of extracellular pH and lactate maps obtained in in vivo rat brain gliomas by proton spectroscopic imaging"
    Chantal Rémy, Ph.D.,  Université Joseph Fourier, Grenoble, France
  • 11:30-11:50: "Microenvironmental pH and Drug Resistance in Tumors"
    Natarajan Raghunand, Ph.D., University of Arizona, Tucson, AZ, USA
  • 11:50-12:10: Proffered Papers:

    Use of 1H Magnetic Resonance Spectroscopic Imaging in Managing Recurrent Glioma Patients Undergoing Radiosurgery"
    Antoinette A. Chan, University of California, San Francisco, CA, USA

    "Measurement of Tumor Glycolysis in In Vivo Using 13C MR Spectroscopy"
    Harish Poptani, Ph.D., University of Pennsylvania, Philadelphia, PA, USA
12:10-13:30 Lunch
13:30-14:15 Negendank Memorial Lecture:
"Clinical MRS: Where and when can it make a difference?"
Speaker: John Kurhanewicz, Ph.D., University of California, San Francisco, CA, USA
14:15-14:55 Poster Discussions:
  • "Assignment of Polyunsaturated Lipids in the BT4C Gliomas Undergoing Gene Therapy-Induced Programmed Cell Death by 1H NMR Spectroscopy"
    Julian L. Griffin, Ph.D., Imperial College of Science, Technology & Medicine, London, England, UK
  • "Correcting the Arterial Input Function for T2* Shortening in Perfusion and Permeability Studies of Abdominal and Thoracic Metasteses at 3.0 Tesla"
    Cedric de Bazelaire, M.D., Beth Israel Deaconess Medical Center, Boston, MA, USA
  • "Integrating In Vivo MRI and MRSI Data for Non-Invasive Classification of Gliomas"
    Xiaojuan Li, M.S., University of California, San Francisco, CA, USA
  • "Differentiation of Metasteses from High-Grade Gliomas using Short Echo Time 1H MR Spectroscopy"
    Kirstie S. Opstad, B.Sc., St. George's Hospital Medical School, London, England, UK
  • "Intratumor and Intertumor Heterogeneity in Contrast Agent Kinetics as Assesses by Functional MRI - Initial Results with Implications for Metastasis"
    Arvind P. Pathak, Ph.D., Johns Hopkins University School of Medicine, Baltimore, MD, USA
14:55-16:10 Poster Session 2: Functional and Molecular Assessment of Cancer
16:10-17:00 Free time
17:00-18:00 Prospects of High Magnetic Fields in Cancer
Chair: Jeffry R. Alger, Ph.D., UCLA School of Medicine, Los Angeles, CA, USA

Intro lectures, followed by roundtable discussion
  • 17:00-17:20: "Advantages of High Magnetic Fields in Cancer"
    Michael Garwood, Ph.D., University of Minnesota, Minneapolis, MN, USA
  • 17:20-17:40: "Disadvantages of High Magnetic Fields in Cancer"
    Truman R. Brown, Ph.D., Columbia University, NY, New York, USA
  • 17:40-18:00:  Roundtable discussion

18:00-23:00

 Private Dinner and Reception
Monday, 21 October
07:00-09:00 Breakfast
09:00-09:40 Regulatory issues related to the introduction of new MRI agents
Michael V. Knopp, M.D., The Ohio State University, Columbus, OH, USA
09:40-12:00 Cancer MR: Current role and future directions of Cancer MR:
Generate white paper
Chair: Jeffrey L. Evelhoch, Ph.D., Wayne State University, Detroit, MI, USA

The purpose of this session is to reach a consensus on what the ISMRM MR of Cancer Study Group considers to be areas of MR research which, over the next few years, are most likely to advance our understanding of the fundamental biology of cancer and to advance the use of MR in the diagnosis and management of patients with cancer. This consensus will be briefly summarized in a paper (a so-called "white paper") that will be appropriate for distribution to funding agencies and administrators to make clear the Study Group's position on this topic and, hopefully, encourage them to support research in these areas.
End of Workshop

12:00-13:30

 Lunch